The Wolverine Protocol for dogs
Also searched as: wolverine stack, BPC-157 and TB-500 together
The short answer
BPC-157 combined with TB-500 — the most widely discussed regenerative stack, investigated for soft tissue and orthopaedic injury.
What it is and why these compounds
The Wolverine Protocol pairs BPC-157 with TB-500. The rationale is complementary mechanisms: BPC-157 is investigated for angiogenesis and tendon-to-bone healing, while TB-500 is associated with actin-mediated cell migration and collagen deposition. In the published literature the two are more often studied together than compared against each other, though no controlled canine trial of the combination exists. The practical appeal is that their dosing schedules differ — BPC-157 daily, TB-500 weekly — so the combined burden is lower than two daily injections. The significant caveat is TB-500's cancer contraindication, which governs whether this stack is appropriate at all.
What the studies actually show
Evidence review
Unlike most "stack" pages, the evidence here does not support synergy. Exactly one primary study has given BPC-157 and TB-500 together — a 2026 rat Achilles tendon experiment — and the combination did not outperform either peptide alone, with TB-500 alone producing the clearest gains. Everything else is a mechanistic rationale drawn from separate studies: BPC-157 drives angiogenesis (VEGFR2/eNOS) and tendon-fibroblast migration, while TB-500 (thymosin beta-4) promotes cell migration, survival and matrix remodelling. Those mechanisms are complementary on paper, but did not translate into additive healing when tested together. The only genuinely canine data for either compound is a single beagle pharmacokinetic and tolerability study of BPC-157; there are no canine efficacy studies for either peptide, and none for the combination. the pro-angiogenic action of TB-500 also carries a plausible tumour-promotion concern, which is why cancer screening gates this protocol. Bottom line: emerging, largely rodent evidence for each compound alone, and a single negative combination study — the popular claim that the two are better together is not evidence-based.
Compounds in this protocol
Before starting
These are the decisions that determine whether this protocol is appropriate at all.
⚠ Read first
TB-500 is contraindicated in dogs with active or suspected cancer. Screening before starting is not optional — it is the single decision that determines whether this protocol is appropriate.
Caution
TB-500 is banned in competitive racing and is detectable in urine and plasma.
Caution
Running two compounds simultaneously makes it substantially harder to attribute any adverse effect to one of them. Staggering the start by a week or two makes attribution possible.
Example timeline
A representative schedule drawn from the published literature, showing what is monitored and when. Any actual protocol should be set by the veterinarian managing the case.
- 1Day 1Screening and baseline
What owners observe
Before the first dose, cancer screening must be complete — this is the gate for TB-500, not an optional extra. Photograph the injury, record how your dog is bearing weight, and note baseline energy and appetite.
Clinical monitoring
Baseline CBC and chemistry panel. Confirm no known or suspected malignancy. Begin BPC-157 daily and TB-500 at loading dose twice weekly.
- 2Week 2Early response
What owners observe
Increased willingness to bear weight is the earliest reliable signal. Mild swelling at TB-500 injection sites is common and settles within a day.
Clinical monitoring
Palpate for reduced swelling and heat. Re-score gait. Verify injection site rotation for both compounds and use separate sites on separate days.
- 3Week 4Transition
What owners observe
Substantial mobility gains are typical. This is the decision point for continuing, tapering, or stopping.
Clinical monitoring
TB-500 moves to maintenance — half dose, once weekly. BPC-157 continues daily. Repeat imaging where applicable may show tissue consolidation.
- 4Week 8Completion
What owners observe
Full return to normal activity with improvement holding steady. Structured rehabilitation matters more at this stage than extending the protocol.
Clinical monitoring
Follow-up imaging to confirm repair. Discontinue TB-500. BPC-157 may continue at a reduced maintenance schedule for chronic conditions under veterinary direction.
Investigated for
Tendon and ligament injury
Strains, partial tears, and chronic tendinopathies in working, sporting, and active dogs.
Cranial cruciate ligament (CCL) tear
Rupture of the stabilising ligament in the stifle, the single most common orthopaedic injury in dogs.
Post-surgical recovery
Supporting tissue repair, comfort, and return to function after an orthopaedic or soft tissue procedure.
Osteoarthritis
Progressive cartilage loss and joint inflammation, affecting a large share of dogs over eight years old.
Common questions
What is the Wolverine Protocol for dogs?+
BPC-157 combined with TB-500 — the most widely discussed regenerative stack, investigated for soft tissue and orthopaedic injury. It combines BPC-157, TB-500.
Is the Wolverine Protocol safe for dogs?+
TB-500 is contraindicated in dogs with active or suspected cancer. Screening before starting is not optional — it is the single decision that determines whether this protocol is appropriate. TB-500 is banned in competitive racing and is detectable in urine and plasma. Running two compounds simultaneously makes it substantially harder to attribute any adverse effect to one of them. Staggering the start by a week or two makes attribution possible.
How long does the Wolverine Protocol run?+
The example timeline runs from day 1 through week 8. Actual duration should be set by the veterinarian managing the case and adjusted on response.
References
- 1.Biçer O, Adanır O, Güleryüz Y, et al. Effects of BPC-157 and TB-500 on Achilles tendon healing in rats: A histopathological and biomechanical study. Joint Diseases and Related Surgery, 2026. PMID 42542926
- 2.CANINE STUDYHe L, Feng D, Guo H, et al. Pharmacokinetics, distribution, metabolism, and excretion of body-protective compound 157, a potential drug for treating various wounds, in rats and dogs. Frontiers in Pharmacology, 2022. PMID 36588717
- 3.Chang C-H, Tsai W-C, Hsu Y-H, Pang J-HS. The promoting effect of pentadecapeptide BPC 157 on tendon healing involves tendon outgrowth, cell survival, and cell migration. Journal of Applied Physiology, 2011. PMID 21030672
- 4.Hsieh M-J, Liu H-T, Wang C-N, et al. Therapeutic potential of pro-angiogenic BPC157 is associated with VEGFR2 activation and up-regulation. Journal of Molecular Medicine, 2017. PMID 27847966
- 5.Malinda KM, Sidhu GS, Mani H, et al. Thymosin beta4 accelerates wound healing. Journal of Investigative Dermatology, 1999. PMID 10469335
- 6.Xu B, Yang M, Li Z, et al. Thymosin beta4 enhances the healing of medial collateral ligament injury in rat. Regulatory Peptides, 2013. PMID 23523891
- 7.Bock-Marquette I, Saxena A, White MD, et al. Thymosin beta4 activates integrin-linked kinase and promotes cardiac cell migration, survival and cardiac repair. Nature, 2004. PMID 15565145
- 8.Cha H-J, Jeong M-J, Kleinman HK. Role of thymosin beta4 in tumor metastasis and angiogenesis. Journal of the National Cancer Institute, 2003. PMID 14625258
- 9.CANINE STUDYXu C, Sun L, Ren F, et al. Preclinical safety evaluation of body protective compound-157, a potential drug for treating various wounds. Regulatory Toxicology and Pharmacology, 2020. PMID 32334036
- 10.Vasireddi N, Nguyen HH, Ahmed WA, et al. Emerging Use of BPC-157 in Orthopaedic Sports Medicine: A Systematic Review. HSS Journal, 2025. PMID 40756949
- 11.Gwyer D, Wragg NM, Wilson SL Gastric pentadecapeptide body protection compound BPC 157 and its role in accelerating musculoskeletal soft tissue healing. Cell and Tissue Research, 2019. PMID 30915550
- 12.Józwiak M, Bauer M, Kamysz W, Kleczkowska P Multifunctionality and Possible Medical Application of the BPC 157 Peptide — Literature and Patent Review. Pharmaceuticals, 2025. PMID 40005999
- 13.Mayfield CK, et al. Injectable Peptide Therapy: A Primer for Orthopaedic and Sports Medicine Physicians. American Journal of Sports Medicine, 2026. PMID 41476424
- 14.Kleinman HK, Sosne G Thymosin β4 Promotes Dermal Healing. Vitamins and Hormones, 2016. PMID 27450738
- 15.Philp D, Kleinman HK Animal studies with thymosin beta, a multifunctional tissue repair and regeneration peptide. Annals of the New York Academy of Sciences, 2010. PMID 20536453
- 16.Goldstein AL, Hannappel E, Sosne G, Kleinman HK Thymosin β4: a multi-functional regenerative peptide. Basic properties and clinical applications. Expert Opinion on Biological Therapy, 2012. PMID 22074294
- 17.Ho EN, Kwok WH, Lau MY, et al. Doping control analysis of TB-500, a synthetic version of an active region of thymosin β4, in equine urine and plasma. Journal of Chromatography A, 2012. PMID 23084823
- 18.Delcourt V, Loup B, Bailly-Chouriberry L, et al. TB500/TB1000 and SGF1000: A scientific approach for a better understanding of misbranded and unapproved drugs. Drug Testing and Analysis, 2023. PMID 36482504
Where to source research peptides
Compound quality is the variable most owners underestimate. Purity, accurate peptide content, and correct labelling determine whether any published dosing figure means anything at all. Pet & Peps Research publishes third-party testing on the compounds covered in this guide and supports this site.
Educational information — not veterinary medical advice
Everything on this page is compiled from published peer-reviewed literature for educational and research purposes. It does not establish a veterinarian-client-patient relationship (VCPR) and is not a substitute for veterinary examination and diagnosis. Most compounds described here are investigational or used off-label and are not FDA-approved for these purposes in dogs. Extralabel drug use in animals requires a valid VCPR and the direct supervision of a licensed veterinarian under AMDUCA (21 U.S.C. §360b). Dosing figures are reported as they appear in the source literature and are not recommendations.